【Case Study】New Approach Methods NAMs
Learn more about our NAMs platform 2D vs 3D hepatocyte model for acetaminophen-induced toxicity A 2D HepG2 culture and 3D HepG2 spheroid system can be used to evaluate acetaminophen-induced toxicity with image-based analysis and viability readouts, illustrating how 3D systems can support longer-term, repetitive exposure designs. Cytokine Release Assay (CRA) for immune activation risk Medicilon […]
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche
Recently, MediLink Therapeutics entered into a new exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pharmaceutical giant, for YL201, an antibody-drug conjugate (ADC) targeting B7H3.This landmark deal, featuring an upfront payment and near-term milestone payments exceeding USD 570 million, not only serves as a strong recognition of the substantial clinical value and […]
AACR 2026
Friday, April 17, 2026,
to Wednesday, April 25, 2026
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
Learn more about our CMC Capability Route, Solid-State, and Impurity Optimization (Small-Molecule API) Program Type: Small-molecule APICMC Focus: Route optimization, solid-state control, impurity management Overview In a separate small-molecule program, Medicilon re-engineered the API synthetic route and solid form strategy to significantly improve manufacturability, safety, and analytical control. The work integrated process chemistry, solid-state science, […]
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Learn more about our CMC Capability IND Completion in 12 Months (Small-Molecule NCE) Program Type: Small-molecule New Chemical Entity (NCE)Scope: End-to-end CMC (API process development, analytics, GMP manufacturing, regulatory documentation)Outcome: IND approval achieved ~12 months from contract signing Project Overview Medicilon supported a small-molecule NCE program with fully integrated CMC services, enabling IND approval within […]
DDC 2026
Monday, April 14, 2026,
to Thursday, April 16, 2026
SOT 2026
Sunday, March 22, 2026,
to Wednesday, March 25, 2026
Building a New-Drug Expressway Together, Medicilon 2025 Year-End Review
For Medicilon, 2025 was a year of steady execution and meaningful progress, strengthening our foundations, expanding our global footprint, and working closely with partners around the world to move innovative medicines forward. Throughout the year, we continued to integrate discovery, development, and regulatory readiness, connecting early scientific innovation with global clinical and regulatory pathways. Step […]
Medicilon Congratulates AI-Driven Biotech Insilico Medicine on Its HKEX Debut in Hong Kong’s Largest Biotech IPO of 2025
On December 30, Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 3696.HK). The offering raised HK$2.277 billion, making it the largest biotech IPO in Hong Kong in 2025 and the first AI-driven biotech company to list under Listing […]
Boston Non-Tumor Models Innovation
Learn more about our Non Tumor Model 1. Imiquimod (IMQ) Induced Psoriasis model Imiquimod (IMQ) Induced Psoriasis model. Female Balb/c mice (9 weeks old) were treated topically with imiquimod (IMQ) on the ear and dorsal skin for seven consecutive days (A). Psoriasis Area and Severity Index (PASI) (B), dorsal skin thickness change (%) (C), and […]
